Market Snapshot

S&P Futures
4,139.00
Dow Futures
33,834.00
NASDAQ Futures
13,845.00

The fundamentals of KemPharm Inc. (KMPH) lend themselves to long-term investors

Related Topics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on whatsapp
WhatsApp

KemPharm, Inc. (NASDAQ: KMPH)has performed -15.80% so far this year, while over the last seven days it has performed -4.8%. Over a 3-month period, the stock’s price index had a 56.38% uptick and a -46.42% drop. It had a -18.56% performance in the last six months and an 80.24% performance over the last 52 weeks.

A specialty pharmaceutical company, KemPharm, Inc. (NASDAQ: KMPH) focuses on discovering and developing groundbreaking prodrugs that can treat serious medical conditions with the use of its proprietary LAT technology.

Latest Development

March 02, 2021, The U.S. Food and Drug Administration has approved KemPharm, Inc.’s (NASDAQ: KMPH) New Drug Application for AZSTARYS, a once-daily product, for young people with attention deficit hyperactivity disorder (ADHD). In AZSTARYS, KemPharm’s prodrug of d-methylphenidate (d-MPH) serdexmethylphenidate (SDX) has been co-formulated with immediate-release d-MPH.

In accordance with the definitive collaboration and license agreement between KemPharm and an affiliate of Gurnet Point Capital (GPC), Corium, Inc. (Corium) will lead the commercialization of AZSTARYS. As early as the second half of 2021, Corium expects AZSTARYS to be commercially available in the U.S.

KemPharm has been awarded a regulatory milestone payment under the License Agreement following FDA approval of AZSTARYS, and KemPharm is working with GPC to evaluate the related provisions and amounts. KemPharm may be eligible for up to $468 million in regulatory and sales milestone payments under the License Agreement with tiered royalty payments, and potential percentages of up to 10% of net sales, for net sales within the U.S., and up to 3% of net sales outside the U.S.

Today, KemPharm will hold a conference call and live audio webcast with a slide presentation to discuss FDA approval of the AZSTARYS NDA to be held at 8:30 a.m. ET. Investors can rely on the following numbers to attend the conference call:

(866) 395-2480 (U.S.)

(678) 509-7538 (international)

Conference ID: 4272912

A webcast presentation with accompanying audio will be available at http://investors.kempharm.com/. From tomorrow, March 3, 2021, until approximately 9:30 AM ET, you can find an archive of the webcast and presentation.

Finally,

Investors are surely following the suggestions of Wall Street analysts about KemPharm Inc. Analysts agree that KMPH has a Buy rating based on current evaluations. Using a simple numeric scale of one to five, the brokerage firm’s current average recommendation for the stock reads 2.00. A value of 0 to 2 implies a Buy recommendation while a value of 2 to 3 suggests Hold while above 3 indicates Sell. At present, two Wall Street analysts are recommending a Buy rating for the stock.

Sign up for our FREE Newsletter and get:
Sign up for our FREE Newsletter and get:

SOCIAL LINKS

Latest Posts